Omeros (OMER) Non-Current Assets (2010 - 2026)
Omeros (OMER) reported Non-Current Assets of $105.8 million for Q1 2026, down 23.86% on a YoY basis from $139.0 million in Q1 2025, and down 3.77% sequentially from $110.0 million in Q4 2025.
Omeros (OMER) Non-Current Assets (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Non-Current Assets data on file, last reported at $105.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 23.86% year-over-year to $105.8 million; the trailing twelve-month figure through Mar 2026 stood at $460.6 million (down 21.09% YoY), and the FY2025 full-year result was $110.0 million, down 23.08% from the prior year.
- Non-Current Assets slipped to $105.8 million in Q1 2026, from $110.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $169.0 million in Q3 2022 to a low of $105.8 million in Q1 2026.
- A 5-year average of $142.0 million and a median of $143.1 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 449.14% in 2022 and retreated 23.86% in 2026, its largest moves.
- Tracing OMER's Non-Current Assets over 5 years: stood at $147.7 million in 2022, then gained by 8.55% to $160.4 million in 2023, then retreated by 10.86% to $143.0 million in 2024, then retreated by 23.08% to $110.0 million in 2025, then dropped by 3.77% to $105.8 million in 2026.
- Business Quant data shows OMER's Non-Current Assets at $105.8 million in Q1 2026, $110.0 million in Q4 2025, and $113.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | 105.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.82 Mn |
| Dec 31, 2025 | 109.97 Mn |
| Sep 30, 2025 | 113.90 Mn |
| Jun 30, 2025 | 130.92 Mn |
| Mar 31, 2025 | 138.98 Mn |
| Dec 31, 2024 | 142.96 Mn |
| Sep 30, 2024 | 148.41 Mn |
| Jun 30, 2024 | 153.38 Mn |
| Mar 31, 2024 | 156.53 Mn |
| Dec 31, 2023 | 160.37 Mn |
| Sep 30, 2023 | 141.73 Mn |
| Jun 30, 2023 | 138.86 Mn |
| Mar 31, 2023 | 143.10 Mn |
| Dec 31, 2022 | 147.73 Mn |
| Sep 30, 2022 | 169.01 Mn |
| Jun 30, 2022 | 152.92 Mn |
| Mar 31, 2022 | 159.04 Mn |
| Dec 31, 2021 | 171.31 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 32.99 Mn |